Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK‐1 Inhibitor, After Short‐Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials

समान संसाधन

• Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection
  द्वारा: Namour, Florence, और अन्य
  प्रकाशित: (2015)
• JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib
  द्वारा: Traves, Paqui G, और अन्य
  प्रकाशित: (2021)
• Safety, pharmacokinetics and pharmacodynamics of GLPG0974, a potent and selective FFA2 antagonist, in healthy male subjects
  द्वारा: Namour, Florence, और अन्य
  प्रकाशित: (2016)
• Influence of age and renal impairment on the steady state pharmacokinetics of filgotinib, a selective JAK1 inhibitor
  द्वारा: Namour, Florence, और अन्य
  प्रकाशित: (2018)
• Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes
  द्वारा: Genovese, Mark, और अन्य
  प्रकाशित: (2018)